Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesity

详细信息	查看全文 | 推荐本文 |

• 作者：Hideaki Nakatsuji^a ; Ken Kishida^a ; ^b ; ^{kkishida@imed2.med.osaka-u.ac.jp} ; Tohru Funahashi^a ; ^b ; Iichiro Shimomura^a ; The Senri Study II Group¹
• 关键词：Thiazolidinediones ; Pioglitazone ; S100A8/A9 (MRP8/14) complex ; Abdominal obesity
• 刊名：Diabetes Research and Clinical Practice
• 出版年：2012
• 期刊代码：78_01688227
• 类别：med
• 出版时间：March, 2012
• 卷：95
• 期：3
• 页码：e58-e60
• 文件大小：255 K

摘要

We measured circulating S100A8/A9 (MRP8/14) complex levels before and after 3-month treatment with pioglitazone in type 2 diabetic patients. The results showed that pioglitazone reduced circulating S100A8/A9 complex levels, without changing body mass index, in type 2 diabetic patients with abdominal obesity.